We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
International Markets and Illumina (ILMN): A Deep Dive for Investors
Read MoreHide Full Article
Have you evaluated the performance of Illumina's (ILMN - Free Report) international operations during the quarter that concluded in September 2025? Considering the extensive worldwide presence of this genetic testing tools company, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth.
The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its financial success and growth path. It has become essential for investors to comprehend how much a company relies on these foreign markets, as this understanding reveals the firm's potential for consistent earnings, its capacity to harness different economic cycles, and its overall growth prospects.
Presence in international markets can act as a hedge against domestic economic downturns and provide access to faster-growing economies. However, this diversification also brings complexities due to currency fluctuations, geopolitical risks and differing market dynamics.
While analyzing ILMN's performance for the last quarter, we found some intriguing trends in revenues from its overseas segments that Wall Street analysts commonly model and monitor.
The company's total revenue for the quarter stood at $1.08 billion, increasing 0.4% year over year. Now, let's delve into ILMN's international revenue breakdown to gain insights into the significance of its operations beyond home turf.
Decoding ILMN's International Revenue Trends
Europe accounted for 28.5% of the company's total revenue during the quarter, translating to $309 million. Revenues from this region represented a surprise of -0.79%, with Wall Street analysts collectively expecting $311.46 million. When compared to the preceding quarter and the same quarter in the previous year, Europe contributed $310 million (29.3%) and $291 million (26.9%) to the total revenue, respectively.
Greater China generated $52 million in revenues for the company in the last quarter, constituting 4.8% of the total. This represented a surprise of +22.12% compared to the $42.58 million projected by Wall Street analysts. Comparatively, in the previous quarter, Greater China accounted for $63 million (6%), and in the year-ago quarter, it contributed $75 million (6.9%) to the total revenue.
International Revenue Predictions
It is projected by analysts on Wall Street that Illumina will post revenues of $1.1 billion for the ongoing fiscal quarter, a decline of 0.7% from the year-ago quarter. The expected contributions from Europe and Greater China to this revenue are 29%, and 4%, translating into $317.58 million, and $43.41 million, respectively.
Analysts expect the company to report a total annual revenue of $4.26 billion for the full year, marking a decrease of 2.5% compared to last year. The expected revenue contributions from Europe and Greater China are projected to be 28.9% ($1.23 billion), and 5.2% ($220.99 million) of the total revenue, in that order.
Closing Remarks
The dependency of Illumina on global markets for its revenues presents a mix of potential gains and hazards. Thus, monitoring the trends in its overseas revenues can be a key indicator for predicting the firm's future performance.
In an environment where global interconnections and geopolitical skirmishes are intensifying, Wall Street analysts keep a keen eye on these trends, particularly for firms with overseas operations, to adjust their earnings predictions. Moreover, a range of other aspects, including how a company fares in its home country, significantly affects these projections.
At Zacks, a company's changing earnings outlook is given considerable attention due to its proven, strong influence on a stock's price performance in the near term. The connection here is straightforward and positive: when earnings estimates are revised upward, the stock price generally follows suit, increasing as well.
Boasting a remarkable track record that's been externally verified, the Zacks Rank, our unique stock rating system, leverages changes in earnings projections to function as a reliable gauge for predicting short-term stock price movements.
A Review of Illumina's Recent Stock Market Performance
The stock has witnessed an increase of 21% over the past month versus the Zacks S&P 500 composite's an increase of 2.4%. In the same interval, the Zacks Medical sector, to which Illumina belongs, has registered an increase of 6.8%. Over the past three months, the company's shares saw an increase of 30.7%, while the S&P 500 increased by 8.2%. In comparison, the sector experienced an increase of 13.3% during this timeframe.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
International Markets and Illumina (ILMN): A Deep Dive for Investors
Have you evaluated the performance of Illumina's (ILMN - Free Report) international operations during the quarter that concluded in September 2025? Considering the extensive worldwide presence of this genetic testing tools company, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth.
The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its financial success and growth path. It has become essential for investors to comprehend how much a company relies on these foreign markets, as this understanding reveals the firm's potential for consistent earnings, its capacity to harness different economic cycles, and its overall growth prospects.
Presence in international markets can act as a hedge against domestic economic downturns and provide access to faster-growing economies. However, this diversification also brings complexities due to currency fluctuations, geopolitical risks and differing market dynamics.
While analyzing ILMN's performance for the last quarter, we found some intriguing trends in revenues from its overseas segments that Wall Street analysts commonly model and monitor.
The company's total revenue for the quarter stood at $1.08 billion, increasing 0.4% year over year. Now, let's delve into ILMN's international revenue breakdown to gain insights into the significance of its operations beyond home turf.
Decoding ILMN's International Revenue Trends
Europe accounted for 28.5% of the company's total revenue during the quarter, translating to $309 million. Revenues from this region represented a surprise of -0.79%, with Wall Street analysts collectively expecting $311.46 million. When compared to the preceding quarter and the same quarter in the previous year, Europe contributed $310 million (29.3%) and $291 million (26.9%) to the total revenue, respectively.
Greater China generated $52 million in revenues for the company in the last quarter, constituting 4.8% of the total. This represented a surprise of +22.12% compared to the $42.58 million projected by Wall Street analysts. Comparatively, in the previous quarter, Greater China accounted for $63 million (6%), and in the year-ago quarter, it contributed $75 million (6.9%) to the total revenue.
International Revenue Predictions
It is projected by analysts on Wall Street that Illumina will post revenues of $1.1 billion for the ongoing fiscal quarter, a decline of 0.7% from the year-ago quarter. The expected contributions from Europe and Greater China to this revenue are 29%, and 4%, translating into $317.58 million, and $43.41 million, respectively.Analysts expect the company to report a total annual revenue of $4.26 billion for the full year, marking a decrease of 2.5% compared to last year. The expected revenue contributions from Europe and Greater China are projected to be 28.9% ($1.23 billion), and 5.2% ($220.99 million) of the total revenue, in that order.
Closing Remarks
The dependency of Illumina on global markets for its revenues presents a mix of potential gains and hazards. Thus, monitoring the trends in its overseas revenues can be a key indicator for predicting the firm's future performance.
In an environment where global interconnections and geopolitical skirmishes are intensifying, Wall Street analysts keep a keen eye on these trends, particularly for firms with overseas operations, to adjust their earnings predictions. Moreover, a range of other aspects, including how a company fares in its home country, significantly affects these projections.
At Zacks, a company's changing earnings outlook is given considerable attention due to its proven, strong influence on a stock's price performance in the near term. The connection here is straightforward and positive: when earnings estimates are revised upward, the stock price generally follows suit, increasing as well.
Boasting a remarkable track record that's been externally verified, the Zacks Rank, our unique stock rating system, leverages changes in earnings projections to function as a reliable gauge for predicting short-term stock price movements.
At present, Illumina holds a Zacks Rank #3 (Hold). This ranking implies that its near-term performance might mirror the overall market movement. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
A Review of Illumina's Recent Stock Market Performance
The stock has witnessed an increase of 21% over the past month versus the Zacks S&P 500 composite's an increase of 2.4%. In the same interval, the Zacks Medical sector, to which Illumina belongs, has registered an increase of 6.8%. Over the past three months, the company's shares saw an increase of 30.7%, while the S&P 500 increased by 8.2%. In comparison, the sector experienced an increase of 13.3% during this timeframe.